Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Role of statins in the treatment of multiple sclerosis.
The natural course of clinically isolated syndrome in pediatric patients.
Fatigue and fatigability in neurologic illnesses: Proposal for a unified taxonomy.
Phenytoin protects central axons in experimental autoimmune encephalomyelitis.
A molecular link between the active component of marijuana and Alzheimer's disease pathology.
The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis.
Interpretation and visualization of non-linear data fusion in kernel space: study on metabolomic characterization of progression of multiple sclerosis.
IFN-γ Signaling to Astrocytes Protects from Autoimmune Mediated Neurological Disability.
Reward responsiveness and fatigue in multiple sclerosis.
Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis.
Novartis updates US label on Gilenya® following discussions with the FDA
Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: report of six cases.
Cytokines and Disability in Interferon-β-1b Treated and Untreated Women with Multiple Sclerosis.
Mechanism for p38α-mediated experimental autoimmune encephalomyelitis.
The Symptom Inventory Disability-Specific Short Forms for Multiple Sclerosis: Reliability and Factor Structure.
Association of SNPs rs6498169 and rs10984447 with multiple sclerosis in Saudi Patients: a model of the usefulness of familial aggregates in identifying genetic linkage in a multifactorial disease.
Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation.
Risk of invasive pneumococcal disease in people admitted to hospital with selected immune-mediated diseases: record linkage cohort analyses.
Outcome and survival of asymptomatic PML in natalizumab-treated MS patients.
Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccination.
Correlates of Executive Functions in Multiple Sclerosis Based on Structural and Functional MR Imaging: Insights from a Multicenter Study.
Over six cups of coffee a day may reduce the risk of developing multiple sclerosis.
Relationship between HLA-DRB1 polymorphism and susceptibility or resistance to multiple sclerosis in Caucasians: a meta-analysis of non-family-based studies.
Psychiatric disorders in neurology.
CCSVI and MS: no meaning, no fact.
Pages
« first
‹ previous
…
127
128
129
130
131
132
133
134
135
…
next ›
last »